Finally! Be free from smoking

sam wrote an intriguing post today on

Here’s a little taster
… Oncothyreon is developing a potential cancer vaccine Stimuvax. The investigational therapeutic cancer vaccine is being developed by Merck KGaA of Darmstadt, Germany, under a license agreement with Oncothyreon. MUC1, a protein antigen is over expressed in all cancer cells, including lung, breast and colorectal. Stimuvax is thought to work by stimulating the body’s immune system to identify and destroy cancer cells expressing MUC1.

Read the rest of this post here